Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study

ConclusionsThe mPFS in the Her2-zero group was almost twice that of the Her2-low group, but the difference was not statistically significant. mPFS was significantly longer in the HER2-zero group compared to the HER2-low group in patients receiving ribociclib. More prospective studies are needed to understand the actual consequences of this biomarker.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research